AAVB-039

N/A

Report date: 2025/10/15 17:03:27

Base Information

Drug NameAAVB-039
Drug Alias NameABCA4 gene therapy (AAVantgarde Bio)AAVB-039
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionRetinal-specific phospholipid-transporting ATPase ABCA4 gene transference
TargetsRetinal-specific phospholipid-transporting ATPase ABCA4
Therapy Area/IndicationsStargardt Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAAVantgarde Bio SRL
China Registration ClassN/A

Develop Information

Active CompaniesAAVantgarde Bio UK LtdAAVantgarde Bio SRL
Inactive CompaniesN/A
Active IndicationsStargardt Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A